Antithrombin Market Size, Trends and Insights By Application Type (Research, Therapeutics, Diagnostics), By Source (Goat milk, Human ), By Dosage (Liquid, Lyophilized), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033
Report Snapshot
| Study Period: | 2024-2033 |
| Fastest Growing Market: | Asia-Pacific |
| Largest Market: | Europe |
Major Players
- Lee Biosolutions
- Scripps Laboratories
- Octapharma AG
- LFB USA
- Others
Reports Description
According to Custom Market Insights (CMI), The Global Antithrombin Market Size was valued at USD 502.4 million in 2021 and is expected to reach USD 508.32 million in 2022, and is estimated to reach USD 735.12 million by the end of 2030 at a CAGR of approximately 4.8% during the forecast period 2022-2030.
Antithrombin is considered a blood thinner in the human blood, which prevents it from clotting. It is a natural component contained in the human blood, which behaves as a thinner to avoid the formation of clots. It is used during surgical procedures to prevent the blood from clotting and hence maintain the normal blood flow of the individual’s body. In cases where this component of antithrombin is found to be low in the body of the individual, it is externally induced during the surgical procedure to maintain the blood viscosity.
Lack of antithrombin in the individual’s body leads to multiple complications during a surgical procedure and even during the occurrence of local injuries on the individual’s body. The blood flow cannot be controlled naturally by the body’s system as a result of the failure of the individual’s defense mechanism. Excessive blood flow occurs in such individuals, which emerges as a life-threatening condition for the person. Complicated procedures in the field of surgery, such as cardiopulmonary bypass, utilize the component of antithrombin to oxygenate the extracorporeal membrane of the organ.
The surgery procedure becomes extremely fluent and easy with the use of external antithrombin, which helps maintain the blood viscosity. Certain parameters which denote the presence of antithrombin in the individual’s blood insufficiently amount help to judge the complications that can occur during the surgical procedure which will be performed on the individual. Surgeons commonly consider the laboratory examinations of antithrombin antigen and antithrombin activity to gauge the viscosity of the blood and the presence of the necessary component, the absence of which might complicate the surgical procedure.
In certain cases, the individual faces or deficiency of antithrombin as a result of inheritance which results as a genetic factor, where necessary precautions are to be taken by the individual during their entire life to prevent excessive blood loss from the body, which can be life-threatening if not monitored closely. Certain conditions have been noted that lead to the deficiency of antithrombin and are termed as an acquired deficiency that is caused due to multiple other diseases which proved to be life-threatening for the individual.
The above two conditions, which have been discussed, emerge as life-threatening risk factors that cause deficiency of antithrombin in the body of the individual and might complicate the surgical procedure, which is harmful to the patient.
The pandemic outbreak significantly impacted the growth of the antithrombin market due to the strict lockdown and restricted movement imposed by the government all over the world.
The strict rules and regulations imposed on the healthcare sector for attending to and treating patients, which hampered regular follow-ups and treatment procedures, significantly impacted the growth of the antithrombin market. These steps were taken to prevent the risk of cross-infection among the infected patients and the medical staff along with the other patients. A common complication during the pandemic, which was noted among the patients, was clotting of blood, which helped boost the antithrombin market. This component of the blood was in huge demand in the healthcare sector during the pandemic to increase the success rate and survival of the patients. The condition of the patient suffering during the pandemic got complicated greatly due to the clotting factor in the individual’s body. The deficiency of antithrombin in the blood was considered a major cause of the complications during the pandemic.
Growth Factors
The rapidly increasing number of patients who suffer from deficiency of antithrombin in the blood has emerged as a major growth factor for the antithrombin market. The huge number of surgical procedures carried out worldwide, which mainly include open heart surgical procedures, have helped to boost the market for antithrombin to a great extent.
The procedures included during hemodialysis are also emerging as a major growth factor for the market. This component of the blood is a protein that is present in the body and performs a major function by preventing clots in the blood. The function of the thrombin is controlled with the help of this component that helps to maintain the viscosity of the blood during surgical procedures. This blood component is mainly produced with the help of the liver, which includes around 432 amino acids. Severe diseases that a person suffers from, such as severe trauma, nephrotic syndrome and liver failure, emerged as the major causes that lead to acquired antithrombin deficiency.
A huge number of people worldwide suffer from this type of deficiency due to the increasing number of high-velocity accidents all over the world. The use of antithrombin has increased to a great extent as a result of this deficiency that is caused in people.
Certain antigen tests are carried out on the individual’s body to measure the presence of antithrombin in the blood to avoid further complications during the surgical procedure.
The huge number of people suffering from coagulation disorders has helped the market to record tremendous revenue during the forecast period. Rapidly increasing modernization worldwide has pushed people towards many unnecessary habits such as alcoholism which hampers the function of the liver and shows a tremendous impact on the production of antithrombin. The key market players have conducted extensive research and development programs to develop advanced medicines in the market to prevent the deficiency of antithrombin in the body. The hospital sector’s huge number of operative procedures has made it a major market for the demand and supply of antithrombin components.
Segmental Insights
Segmentation of the antithrombin market based on Application Type
Based on application type, the therapeutics segment has evolved as the leading market player owing to its huge market share in the global economy. Demand for antithrombin in the therapeutics and healthcare sector has evolved as the major cause for the growth of this segment in the market. The huge number of people who suffer from antithrombin deficiencies resulting from multiple causes require using this blood component to carry out a successful operative procedure.
The increasing number of operative procedures worldwide has boosted the demand for antithrombin in the healthcare sector, mainly attributed to the operative procedure carried out in this field. A huge amount of blood loss is experienced during digital procedures, which can be fatal for the patient’s life and hence needs to be controlled with the help of antithrombin. The genetic causes of antithrombin deficiency are very rare among people and are mainly attributed to acquired causes of deficiency which emerge as the major factors for the lack of this component in the blood.
A few severe disease conditions that result in the deficiency of antithrombin in the body include nephrotic syndrome, severe burns and liver failure. Huge demand for antithrombin was experienced in the healthcare sector for therapeutic application during the pandemic, which presented the clotting of blood as a major reason that resulted in the death of many patients.
- Segmentation of antithrombin market based on Source
Based on the source, the segment of goat milk has emerged as a major market due to the largest contribution it has supported the market with. The component of antithrombin, obtained from goat milk, emerges as the fastest developing segment due to the huge demand it has experienced from the healthcare sector, which experienced its efficacy in clinical trials.
The antithrombin protein obtained from goat milk has emerged to be very useful for treatment procedures and surgeries which has shown a good response worldwide. Key market players Carrying out research and development programs, making more advancements to alter the composition to make it more suitable for the body of human beings. The antithrombin components obtained from human beings also show considerable growth resulting from its extensive demand in the healthcare sector.
- Segmentation of the antithrombin market based on Dosage
Based on dosage, the segment which proves to be a potential reason for the market’s growth is that of lyophilized antithrombin. The other segment that has been discussed under this category includes liquids that have been administered in the form of antithrombin.
Report Scope
| Feature of the Report | Details |
| Market Size in 2021 | USD 502.4 Million |
| Projected Market Size in 2030 | USD 735.12 Million |
| CAGR Growth Rate | 4.8% CAGR (2022-2030) |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Prominent Players | Lee Biosolutions, Scripps Laboratories, Octapharma AG, LFB USA, rEVO Biologics, Grifols, CSL Ltd, Kedrion, and Others |
| Key Segment | By Application Type, Source, Dosage, and Region |
| Report Coverage | Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends |
| Regional Scope | North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America |
| Buying Options | Request tailored purchasing options to fulfil your requirements for research. |
Regional Insights
Based on geography, the region of Asia Pacific has emerged as the largest consumer and fastest developing market owing to the rapid advancements that have been made in the healthcare sector. The huge number of operative procedures carried out in this region has emerged as a major factor in the market’s growth.
The increasing demand for reducing the number of deaths that have taken place during surgical procedures has boosted the demand for antithrombin in the healthcare sector. Europe emerged as the next potential market for antithrombin resulting from the huge demand for human-based antithrombin among the people.
The advanced health care facilities provided to the people by the government have emerged as a major growth factor for the antithrombin market in this sector. The region of North America has also shown considerable growth owing to the rapid development and increasing number of operative procedures carried out in this region.
Recent Developments
- In February 2009, the Food and Drug Administration approved a therapeutic application under the title of ATryn. This therapeutic application was obtained genetically from the goats. This application was administered with a view to and hence blood thinning procedure in the form of antithrombin protein.
- In January 2013 – An LFB company, GTC biotherapeutics, introduced the name change to Revo biologics. The firm disclosed its future commitments to evolve recombinant medicines and drugs.
Key players
- Lee Biosolutions
- Scripps Laboratories
- Octapharma AG
- LFB USA
- rEVO Biologics
- Grifols
- CSL Ltd
- Kedrion
Segments of the antithrombin market covered in the report
By Application Type
- Research
- Therapeutics
- Diagnostics
By Source
- Goat milk
- Human
By Dosage
- Liquid
- Lyophilized
On the basis of Geography
North America
- U.S.
- Canada
- Mexico
- Rest of North America
Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Rest of Asia Pacific
The Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of the Middle East & Africa
Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
- Chapter 1. Preface
- 1.1 Report Description and Scope
- 1.2 Research scope
- 1.3 Research methodology
- 1.3.1 Market Research Type
- 1.3.2 Market research methodology
- Chapter 2. Executive Summary
- 2.1 Global Antithrombin Market, (2022 – 2030) (USD Million)
- 2.2 Global Antithrombin Market : snapshot
- Chapter 3. Global Antithrombin Market – Industry Analysis
- 3.1 Antithrombin Market: Market Dynamics
- 3.2 Market Drivers
- 3.2.1 Surgical Procedures
- 3.2.2 Hemodialysis
- 3.2.3 Preventing Clots In The Blood
- 3.3 Market Restraints
- 3.4 Market Opportunities
- 3.5 Market Challenges
- 3.6 Porter’s Five Forces Analysis
- 3.7 Market Attractiveness Analysis
- 3.7.1 Market attractiveness analysis By Application Type
- 3.7.2 Market attractiveness analysis By Source
- 3.7.3 Market attractiveness analysis By Dosage
- Chapter 4. Global Antithrombin Market- Competitive Landscape
- 4.1 Company market share analysis
- 4.1.1 Global Antithrombin Market: company market share, 2021
- 4.2 Strategic development
- 4.2.1 Acquisitions & mergers
- 4.2.2 New Product launches
- 4.2.3 Agreements, partnerships, cullaborations, and joint ventures
- 4.2.4 Research and development and Regional expansion
- 4.3 Price trend analysis
- 4.1 Company market share analysis
- Chapter 5. Global Antithrombin Market – Application Type Analysis
- 5.1 Global Antithrombin Market overview: By Application Type
- 5.1.1 Global Antithrombin Market share, By Application Type, 2021 and 2030
- 5.2 Research
- 5.2.1 Global Antithrombin Market by Research, 2022 – 2030 (USD Million)
- 5.3 Therapeutics
- 5.3.1 Global Antithrombin Market by Therapeutics, 2022 – 2030 (USD Million)
- 5.4 Diagnostics
- 5.4.1 Global Antithrombin Market by Diagnostics, 2022 – 2030 (USD Million)
- 5.1 Global Antithrombin Market overview: By Application Type
- Chapter 6. Global Antithrombin Market – Source Analysis
- 6.1 Global Antithrombin Market overview: By Source
- 6.1.1 Global Antithrombin Market share, By Source, 2021 and 2030
- 6.2 Goat milk
- 6.2.1 Global Antithrombin Market by Goat milk, 2022 – 2030 (USD Million)
- 6.3 Human
- 6.3.1 Global Antithrombin Market by Human, 2022 – 2030 (USD Million)
- 6.1 Global Antithrombin Market overview: By Source
- Chapter 7. Global Antithrombin Market – Dosage Analysis
- 7.1 Global Antithrombin Market overview: By Dosage
- 7.1.1 Global Antithrombin Market share, By Dosage, 2021 and 2030
- 7.2 Liquid
- 7.2.1 Global Antithrombin Market by Liquid, 2022 – 2030 (USD Million)
- 7.3 Lyophilized
- 7.3.1 Global Antithrombin Market by Lyophilized, 2022 – 2030 (USD Million)
- 7.1 Global Antithrombin Market overview: By Dosage
- Chapter 8. Antithrombin Market – Regional Analysis
- 8.1 Global Antithrombin Market Regional Overview
- 8.2 Global Antithrombin Market Share, by Region, 2021 & 2030 (USD Million)
- 8.3. North America
- 8.3.1 North America Antithrombin Market, 2022 – 2030 (USD Million)
- 8.3.1.1 North America Antithrombin Market, by Country, 2022 – 2030 (USD Million)
- 8.3.1 North America Antithrombin Market, 2022 – 2030 (USD Million)
- 8.4 North America Antithrombin Market, by Application Type, 2022 – 2030
- 8.4.1 North America Antithrombin Market, by Application Type, 2022 – 2030 (USD Million)
- 8.5 North America Antithrombin Market, by Source, 2022 – 2030
- 8.5.1 North America Antithrombin Market, by Source, 2022 – 2030 (USD Million)
- 8.6 North America Antithrombin Market, by Dosage, 2022 – 2030
- 8.6.1 North America Antithrombin Market, by Dosage, 2022 – 2030 (USD Million)
- 8.7. Europe
- 8.7.1 Europe Antithrombin Market, 2022 – 2030 (USD Million)
- 8.7.1.1 Europe Antithrombin Market, by Country, 2022 – 2030 (USD Million)
- 8.7.1 Europe Antithrombin Market, 2022 – 2030 (USD Million)
- 8.8 Europe Antithrombin Market, by Application Type, 2022 – 2030
- 8.8.1 Europe Antithrombin Market, by Application Type, 2022 – 2030 (USD Million)
- 8.9 Europe Antithrombin Market, by Source, 2022 – 2030
- 8.9.1 Europe Antithrombin Market, by Source, 2022 – 2030 (USD Million)
- 8.10 Europe Antithrombin Market, by Dosage, 2022 – 2030
- 8.10.1 Europe Antithrombin Market, by Dosage, 2022 – 2030 (USD Million)
- 8.11. Asia Pacific
- 8.11.1 Asia Pacific Antithrombin Market, 2022 – 2030 (USD Million)
- 8.11.1.1 Asia Pacific Antithrombin Market, by Country, 2022 – 2030 (USD Million)
- 8.11.1 Asia Pacific Antithrombin Market, 2022 – 2030 (USD Million)
- 8.12 Asia Pacific Antithrombin Market, by Application Type, 2022 – 2030
- 8.12.1 Asia Pacific Antithrombin Market, by Application Type, 2022 – 2030 (USD Million)
- 8.13 Asia Pacific Antithrombin Market, by Source, 2022 – 2030
- 8.13.1 Asia Pacific Antithrombin Market, by Source, 2022 – 2030 (USD Million)
- 8.14 Asia Pacific Antithrombin Market, by Dosage, 2022 – 2030
- 8.14.1 Asia Pacific Antithrombin Market, by Dosage, 2022 – 2030 (USD Million)
- 8.15. Latin America
- 8.15.1 Latin America Antithrombin Market, 2022 – 2030 (USD Million)
- 8.15.1.1 Latin America Antithrombin Market, by Country, 2022 – 2030 (USD Million)
- 8.15.1 Latin America Antithrombin Market, 2022 – 2030 (USD Million)
- 8.16 Latin America Antithrombin Market, by Application Type, 2022 – 2030
- 8.16.1 Latin America Antithrombin Market, by Application Type, 2022 – 2030 (USD Million)
- 8.17 Latin America Antithrombin Market, by Source, 2022 – 2030
- 8.17.1 Latin America Antithrombin Market, by Source, 2022 – 2030 (USD Million)
- 8.18 Latin America Antithrombin Market, by Dosage, 2022 – 2030
- 8.18.1 Latin America Antithrombin Market, by Dosage, 2022 – 2030 (USD Million)
- 8.19. The Middle-East and Africa
- 8.19.1 The Middle-East and Africa Antithrombin Market, 2022 – 2030 (USD Million)
- 8.19.1.1 The Middle-East and Africa Antithrombin Market, by Country, 2022 – 2030 (USD Million)
- 8.19.1 The Middle-East and Africa Antithrombin Market, 2022 – 2030 (USD Million)
- 8.20 The Middle-East and Africa Antithrombin Market, by Application Type, 2022 – 2030
- 8.20.1 The Middle-East and Africa Antithrombin Market, by Application Type, 2022 – 2030 (USD Million)
- 8.21 The Middle-East and Africa Antithrombin Market, by Source, 2022 – 2030
- 8.21.1 The Middle-East and Africa Antithrombin Market, by Source, 2022 – 2030 (USD Million)
- 8.22 The Middle-East and Africa Antithrombin Market, by Dosage, 2022 – 2030
- 8.22.1 The Middle-East and Africa Antithrombin Market, by Dosage, 2022 – 2030 (USD Million)
- Chapter 9. Company Profiles
- 9.1 Lee Biosolutions
- 9.1.1 Overview
- 9.1.2 Financials
- 9.1.3 Product Portfolio
- 9.1.4 Business Strategy
- 9.1.5 Recent Developments
- 9.2 Scripps Laboratories
- 9.2.1 Overview
- 9.2.2 Financials
- 9.2.3 Product Portfolio
- 9.2.4 Business Strategy
- 9.2.5 Recent Developments
- 9.3 Octapharma AG
- 9.3.1 Overview
- 9.3.2 Financials
- 9.3.3 Product Portfolio
- 9.3.4 Business Strategy
- 9.3.5 Recent Developments
- 9.4 LFB USA
- 9.4.1 Overview
- 9.4.2 Financials
- 9.4.3 Product Portfolio
- 9.4.4 Business Strategy
- 9.4.5 Recent Developments
- 9.5 rEVO Biologics
- 9.5.1 Overview
- 9.5.2 Financials
- 9.5.3 Product Portfolio
- 9.5.4 Business Strategy
- 9.5.5 Recent Developments
- 9.6 Grifols
- 9.6.1 Overview
- 9.6.2 Financials
- 9.6.3 Product Portfolio
- 9.6.4 Business Strategy
- 9.6.5 Recent Developments
- 9.7 CSL Ltd
- 9.7.1 Overview
- 9.7.2 Financials
- 9.7.3 Product Portfolio
- 9.7.4 Business Strategy
- 9.7.5 Recent Developments
- 9.8 Kedrion
- 9.8.1 Overview
- 9.8.2 Financials
- 9.8.3 Product Portfolio
- 9.8.4 Business Strategy
- 9.8.5 Recent Developments
- 9.9 and Others
- 9.9.1 Overview
- 9.9.2 Financials
- 9.9.3 Product Portfolio
- 9.9.4 Business Strategy
- 9.9.5 Recent Developments
- 9.1 Lee Biosolutions
List Of Figures
Figures No 1 to 23
List Of Tables
Tables No 1 to 77
Report Methodology
In order to get the most precise estimates and forecasts possible, Custom Market Insights applies a detailed and adaptive research methodology centered on reducing deviations. For segregating and assessing quantitative aspects of the market, the company uses a combination of top-down and bottom-up approaches. Furthermore, data triangulation, which examines the market from three different aspects, is a recurring theme in all of our research reports. The following are critical components of the methodology used in all of our studies:
Preliminary Data Mining
On a broad scale, raw market information is retrieved and compiled. Data is constantly screened to make sure that only substantiated and verified sources are taken into account. Furthermore, data is mined from a plethora of reports in our archive and also a number of reputed & reliable paid databases. To gain a detailed understanding of the business, it is necessary to know the entire product life cycle and to facilitate this, we gather data from different suppliers, distributors, and buyers.
Surveys, technological conferences, and trade magazines are used to identify technical issues and trends. Technical data is also gathered from the standpoint of intellectual property, with a focus on freedom of movement and white space. The dynamics of the industry in terms of drivers, restraints, and valuation trends are also gathered. As a result, the content created contains a diverse range of original data, which is then cross-validated and verified with published sources.
Statistical Model
Simulation models are used to generate our business estimates and forecasts. For each study, a one-of-a-kind model is created. Data gathered for market dynamics, the digital landscape, development services, and valuation patterns are fed into the prototype and analyzed concurrently. These factors are compared, and their effect over the projected timeline is quantified using correlation, regression, and statistical modeling. Market forecasting is accomplished through the use of a combination of economic techniques, technical analysis, industry experience, and domain knowledge.
Short-term forecasting is typically done with econometric models, while long-term forecasting is done with technological market models. These are based on a synthesis of the technological environment, legal frameworks, economic outlook, and business regulations. Bottom-up market evaluation is favored, with crucial regional markets reviewed as distinct entities and data integration to acquire worldwide estimates. This is essential for gaining a thorough knowledge of the industry and ensuring that errors are kept to a minimum.
Some of the variables taken into account for forecasting are as follows:
• Industry drivers and constraints, as well as their current and projected impact
• The raw material case, as well as supply-versus-price trends
• Current volume and projected volume growth through 2030
We allocate weights to these variables and use weighted average analysis to determine the estimated market growth rate.
Primary Validation
This is the final step in our report’s estimating and forecasting process. Extensive primary interviews are carried out, both in-person and over the phone, to validate our findings and the assumptions that led to them.
Leading companies from across the supply chain, including suppliers, technology companies, subject matter experts, and buyers, use techniques like interviewing to ensure a comprehensive and non-biased overview of the business. These interviews are conducted all over the world, with the help of local staff and translators, to overcome language barriers.
Primary interviews not only aid with data validation, but also offer additional important insight into the industry, existing business scenario, and future projections, thereby improving the quality of our reports.
All of our estimates and forecasts are validated through extensive research work with key industry participants (KIPs), which typically include:
• Market leaders
• Suppliers of raw materials
• Suppliers of raw materials
• Buyers.
The following are the primary research objectives:
• To ensure the accuracy and acceptability of our data.
• Gaining an understanding of the current market and future projections.
Data Collection Matrix
| Perspective | Primary research | Secondary research |
| Supply-side |
|
|
| Demand-side |
|
|
Market Analysis Matrix
| Qualitative analysis | Quantitative analysis |
|
|
Key players
- Lee Biosolutions
- Scripps Laboratories
- Octapharma AG
- LFB USA
- rEVO Biologics
- Grifols
- CSL Ltd
- Kedrion
- Others
FAQs
“Asia Pacific” region will lead the global Antithrombin market during the forecast period 2022 to 2030.
The key factors driving the market is Surgical Procedures, Hemodialysis, Preventing Clots In The Blood
The key players operating in the Antithrombin market are Lee Biosolutions, Scripps Laboratories, Octapharma AG, LFB USA, rEVO Biologics, Grifols, CSL Ltd, Kedrion.
The global Antithrombin market is expanding growth with a CAGR of approximately 4.1% during the forecast period (2022 to 2030).
The global Antithrombin market size was valued at USD 490.4 Million in 2021 and it is projected to reach around USD 725.2 Million by 2030.